Arneson, Chase

Chase is a Research Analyst at Fisher Investments and has been with the firm since 2013.

Prescription Drug Price Politics and Pharmaceuticals/Biotech Stocks


Capping prescription drug prices would be a negative for the industry, but even if the idea became legislation, it isn’t likely to pass through the political gauntlet.


Get a weekly roundup of our market insights.Sign up for the MarketMinder email newsletter. Learn more.